Feed BAX
BA

Baxter International

BAX · NYSE

$24.36 +1.92% (+$0.46)
1M +2.05%
Market Cap $12.6B
P/E Ratio -
Div. Yield 0.16%
ROE 16.60%

Bulios Fair Price

$18.13

25.6% downside

Current Price

$24.36

Undervalued Fair Value Overvalued

According to Bulios Fair Price, BAX is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Moderate
4/9
Valuation
53 /100
Fair
P/S 1.10x
P/B 2.03x
P/FCF 18.58x
Growth
24 /100
Declining
FCF growth 17.54%
Book val. growth 1.66%
Rev. growth 3.79%
Profitability
24 /100
Weak
Net margin 9.27%
Op. margin 2.39%
FCF margin 5.91%
Quality
7 /100
Poor
ROE 16.60%
ROA 5.37%
Asset turnover 0.58x
Debt
24 /100
High
Current ratio 1.95x
Int. coverage -0.70x
Net debt/EBITDA 10.02x
Stability
56 /100
Moderate
Rev. volatility 1.67%
EPS volatility 172.55%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about BAX
Online

About the company

Baxter International Inc. (BAX) is an American healthcare company specializing in the development, manufacture, and distribution of medical devices, pharmaceutical products, and biological therapies. With a broad portfolio of products focused on the care of patients with hemophilia, kidney diseases, immune disorders, and other serious health conditions, Baxter is one of the leading players in the healthcare industry. The company is known for its emphasis on innovation and quality, enabling it to provide top-notch solutions to improve the health and quality of life of patients. Baxter International also invests in research and development of new treatment methods and technologies. Baxter International Inc. (BAX) shares could be suitable for investors looking for opportunities in the healthcare sector with a focus on innovation and a broad therapeutic portfolio.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

CEO

Andrew Hider

Employees

37,500

Headquarters

Deerfield

Upcoming events

29 OCT

Earnings

Upcoming earnings report

17d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.